AUTHORS
Sarah E Sartain, MD, Paula Jacobi2, Andrew Yee, PhD3
AFFILIATIONS
1 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
2 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
3 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
ABSTRACT
The alternative complement pathway (AP) amplifies innate immune responses by cleavage and activation of complement factor C3. Excessive AP activation contributes to endothelial injury in inflammatory thrombotic disorders. C3 is a disulfide-linked dimer of its α and β chains. Proteolysis between R748 and S749 by C3 convertases releases the anaphylatoxin, C3a, from the α chain and generates C3b. During AP amplification, C3b binds complement factor B (FB) to orient it for proteolysis by complement factor D (FD). This rapid process releases Ba from FB to produce additional AP C3 convertases.
It has been described that non-complement proteases may also generate active C3 fragments. We previously demonstrated that the serine protease tissue kallikrein 1 (KLK1) cleaves C3, generating a C3b fragment that is similar in size to the canonical C3b. We have also shown that KLK1 is dysregulated in patients with transplant-associated thrombotic microangiopathy and in a murine model of combined immunosuppression and inflammation. KLK1 is a secreted protease with context-dependent roles in vascular regulation and inflammation. Under physiologic conditions, KLK1 signaling promotes vasodilation and regulates vascular permeability, contributing to protective vascular effects. In contrast, KLK1 dysregulation has been described in inflammatory diseases marked by complement activation, such as lupus nephritis, where increased KLK1 activity is associated with vascular inflammation and renal injury. We hypothesized that the KLK1 cleavage product of C3 (kC3b) supports assembly of a functional C3 convertase capable of activating the AP.
Biochemical analyses support KLK1’s selective role within the AP. Recombinant human KLK1 was activated (rhKLK1a, 0.2 µM) and then incubated with C3 (0.29 µM), classical complement component C2 (0.29 µM), or terminal pathway component C5 (0.1 µM) for up to 2 hours. In contrast to C3, immunoblotting showed no increase in either C2 or C5 cleavage products by rhKLK1a. Kinetic analyses further characterized KLK1-mediated C3 cleavage. Incubation of rhKLK1a (0.03 µM) with 10-fold molar excess C3 resulted in detectable C3 cleavage within 1 minute with progressive cleavage over time, yielding an observed second order rate constant of 6.8x102 ± 1.8x102 M-1s-1, consistent with an initiating role for KLK1 in AP activation. To determine whether KLK1-mediated C3 cleavage differs from canonical AP cleavage, kC3b was analyzed by mass spectrometry, which demonstrated marked loss of C3a peptides from kC3b, consistent with release of a C3a-like fragment. However, several distinct peptides from the α chain of kC3b contained adjoining C3a amino acids, suggesting that KLK1 cleaves C3 at one or more sites N-terminal to the canonical R748-S749 scissile bond. To directly test whether KLK1 requires the canonical cleavage site, recombinant mutant C3 containing an R748G substitution was generated. Mutation of the canonical cleavage residue abolished proteolysis of C3 by the AP C3 convertase but not by rhKLK1a, demonstrating that KLK1 cleaves C3 independently of the canonical cleavage site.
To determine if kC3b supports AP amplification, we incubated kC3b (0.29 µM) with FB (0.11 µM) and FD (0.003 µM) and measured Ba generation. Within 10 minutes, significant amounts of Ba were generated in comparison to controls (1,372 ± 23 ng/mL vs. control FB + FD = 117 ± 6 ng/mL, p<0.0001, or vs. control FB + FD + rhKLK1a = 188 ± 14 ng/mL, p<0.0001, respectively; n=3 per group). Likewise, plasma-derived C3b incubated with FB and FD generated Ba levels comparable to that of KLK1-generated C3b (1,353 ± 79 ng/mL vs. 1,372 ± 23 ng/mL, respectively; p=0.94), indicating that kC3b is functionally similar to native C3b as a cofactor for FB proteolysis by FD.
In conclusion, KLK1 selectively cleaves C3 to generate an AP-activating C3b species. These findings identify a previously unrecognized mechanism of AP activation and suggest KLK1-mediated C3 cleavage as a potential therapeutic target in thromboinflammatory diseases characterized by complement dysregulation and vascular injury.
DISCLOSURES
Sarah E Sartain, MD: No relevant conflicts of interest to declare.